Reaktion völlig übertrieben?
| eröffnet am: | 04.10.16 10:49 von: | Senseo2016 |
| neuester Beitrag: | 25.04.21 02:05 von: | Mandybkona |
| Anzahl Beiträge: | 12 | |
| Leser gesamt: | 6698 | |
| davon Heute: | 2 | |
bewertet mit 0 Sternen |
||
|
|
||
04.10.16 10:49
#1
Senseo2016
Reaktion völlig übertrieben?
Spectral Medical's sepsis treatment fails late-stage study
Spectral Medical Inc said its experimental treatment for sepsis - a common, oft-deadly complication of infection - failed a late-stage study, stymieing the company's plans to bring to market the first FDA-approved device for the condition.
Sepsis occurs when the immune system goes into overdrive to fight infection or bacterial toxins, triggering a cascade of physiological changes that can lead to multiple organ failure and death.
Toronto-based Spectral Medical holds North American rights to a system developed by Japan's Toray Industries Inc, designed to restore blood pressure and correct organ dysfunction by using an antibiotic to detoxify the blood.
Once the patient's blood has been extracted, it is passed through two columns to remove a type of toxin, called an endotoxin, which is believed to be a major trigger for sepsis.
The trial did not meet the main goal of absolute reduction in mortality rate at 28 days but did demonstrate beneficial treatment effects, Spectral said on Monday.
"We proved beyond doubt that endotoxin is bad and taking it out is good," and Spectral will discuss with the U.S. Food and Drug Administration the next steps, Chief Executive Paul Walker told Reuters.
http://www.reuters.com/article/us-spectral-medical-study-idUSKCN12319B
Spectral Medical Inc said its experimental treatment for sepsis - a common, oft-deadly complication of infection - failed a late-stage study, stymieing the company's plans to bring to market the first FDA-approved device for the condition.
Sepsis occurs when the immune system goes into overdrive to fight infection or bacterial toxins, triggering a cascade of physiological changes that can lead to multiple organ failure and death.
Toronto-based Spectral Medical holds North American rights to a system developed by Japan's Toray Industries Inc, designed to restore blood pressure and correct organ dysfunction by using an antibiotic to detoxify the blood.
Once the patient's blood has been extracted, it is passed through two columns to remove a type of toxin, called an endotoxin, which is believed to be a major trigger for sepsis.
The trial did not meet the main goal of absolute reduction in mortality rate at 28 days but did demonstrate beneficial treatment effects, Spectral said on Monday.
"We proved beyond doubt that endotoxin is bad and taking it out is good," and Spectral will discuss with the U.S. Food and Drug Administration the next steps, Chief Executive Paul Walker told Reuters.
http://www.reuters.com/article/us-spectral-medical-study-idUSKCN12319B
Angehängte Grafik:
bildschirmfoto_2016-10-04_um_10.png (verkleinert auf 48%)
bildschirmfoto_2016-10-04_um_10.png (verkleinert auf 48%)
04.10.16 10:51
#2
Senseo2016
schlechte NEWS ja, aber kein endgültiges Aus
Da sind Minus 85 Prozent schon sehr viel oder?
Meiner Meinung nach
Meiner Meinung nach
Angehängte Grafik:
bildschirmfoto_2016-10-04_um_10.png (verkleinert auf 34%)
bildschirmfoto_2016-10-04_um_10.png (verkleinert auf 34%)
04.10.16 21:07
#5
Antonp
Ich
Habe die nur auf watch gehabt weil ich in CTSO investiert bin und es war die bessere Entscheidung weil man cytosorb fast überall in der Intensivmedizin einsetzen kan, da sind ganz andere Möglichkeiten als nur Sepsis
05.10.16 07:52
#6
Senseo2016
Danke für die eindeutige Meinung @Antonp
Bin gestern eine spekulative Position zu 0,22 Can $ eingegangen
05.10.16 16:13
#8
Senseo2016
Danke Antonp
Läuft jetzt in Richtung 0,25 - mal sehen was die FDA im persönlichen Gespräch sagt
Läuft jetzt in Richtung 0,25 - mal sehen was die FDA im persönlichen Gespräch sagt
05.10.16 16:38
#9
Senseo2016
Wäre jmd so lieb und würde
einen Realtime link von Kanada einstellen.
Besonders lieben Dank im Voraus
Besonders lieben Dank im Voraus